Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419

New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

H A Kirst 1, G D Sides 1
PMCID: PMC172676  PMID: 2684005

Abstract

Erythromycin and related macrolide antibiotics have recently enjoyed a resurgence of clinical interest. This is a result of activity against organisms which are becoming more prevalent, particularly in immunocompromised hosts and, in addition, better understanding of the unique tissue penetration properties and potential immunomodulating properties of macrolides. Other features of clinical interest possessed by certain of the newer macrolides include the potential for once-daily dosing, resistance to acid degradation in the stomach without enteric coating, and possibly reduced gastrointestinal side effects. The new macrolides are expected to retain the clinical indications of erythromycin, which include upper and lower respiratory tract infections, skin and skin structure infections, and genital tract infections caused by erythromycin-susceptible organisms. In addition, enhanced activity has been demonstrated in animal models and in vitro against toxoplasma, Legionella, Haemophilus, and Campylobacter spp. New macrolide derivatives also show promise to expand the antimicrobial spectrum of erythromycin to include Mycobacterium and Borrelia spp.

Full text

PDF
1419

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agache P., Amblard P., Moulin G., Barrière H., Texier L., Beylot C., Bergoend H. Roxithromycin in skin and soft tissue infections. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):153–156. doi: 10.1093/jac/20.suppl_b.153. [DOI] [PubMed] [Google Scholar]
  2. Aho P., Männistö P. T. Effects of two erythromycins, doxycycline and phenoxymethylpenicillin on human leucocyte chemotaxis in vitro. J Antimicrob Chemother. 1988 Jun;21 (Suppl 500):29–32. doi: 10.1093/jac/21.suppl_d.29. [DOI] [PubMed] [Google Scholar]
  3. Anderson R., Joone G., van Rensburg C. E. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother. 1988 Dec;22(6):923–933. doi: 10.1093/jac/22.6.923. [DOI] [PubMed] [Google Scholar]
  4. Anderson R., Van Rensburg C. E., Eftychis H., Jooné G., van Rensburg A. J. Further studies on erythromycin effects on cellular immune functions in vitro and in vivo. Enhancement of neutrophil motility by erythromycin combined with ascorbate or thiamine. J Antimicrob Chemother. 1982 Nov;10(5):409–417. doi: 10.1093/jac/10.5.409. [DOI] [PubMed] [Google Scholar]
  5. Anderson R., Van Rensburg C. E., Jooné G., Lukey P. T. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):57–68. doi: 10.1093/jac/20.suppl_b.57. [DOI] [PubMed] [Google Scholar]
  6. Benoni G., Cuzzolin L., Leone R., Consolo U., Ferronato G., Bertrand C., Puchetti V., Fracasso M. E. Pharmacokinetics and human tissue penetration of flurithromycin. Antimicrob Agents Chemother. 1988 Dec;32(12):1875–1878. doi: 10.1128/aac.32.12.1875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bright G. M., Nagel A. A., Bordner J., Desai K. A., Dibrino J. N., Nowakowska J., Vincent L., Watrous R. M., Sciavolino F. C., English A. R. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot (Tokyo) 1988 Aug;41(8):1029–1047. doi: 10.7164/antibiotics.41.1029. [DOI] [PubMed] [Google Scholar]
  8. Chantot J. F., Bryskier A., Gasc J. C. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) 1986 May;39(5):660–668. doi: 10.7164/antibiotics.39.660. [DOI] [PubMed] [Google Scholar]
  9. Dette G. A., Knothe H. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leucocytes. J Antimicrob Chemother. 1986 Jul;18(1):73–82. doi: 10.1093/jac/18.1.73. [DOI] [PubMed] [Google Scholar]
  10. Fernandes P. B., Bailer R., Swanson R., Hanson C. W., McDonald E., Ramer N., Hardy D., Shipkowitz N., Bower R. R., Gade E. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986 Dec;30(6):865–873. doi: 10.1128/aac.30.6.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Forsgren A., Schmeling D. Effect of antibiotics of chemotaxis of human leukocytes. Antimicrob Agents Chemother. 1977 Apr;11(4):580–584. doi: 10.1128/aac.11.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Girard A. E., Girard D., English A. R., Gootz T. D., Cimochowski C. R., Faiella J. A., Haskell S. L., Retsema J. A. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 1987 Dec;31(12):1948–1954. doi: 10.1128/aac.31.12.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hara K. [New antimicrobial agent series, XXVII: Rokitamycin]. Jpn J Antibiot. 1987 Nov;40(11):1851–1860. [PubMed] [Google Scholar]
  14. Johnson J. D., Hand W. L., Francis J. B., King-Thompson N., Corwin R. W. Antibiotic uptake by alveolar macrophages. J Lab Clin Med. 1980 Mar;95(3):429–439. [PubMed] [Google Scholar]
  15. Jopling W. H. If I had an attack of malaria. Br J Clin Pract. 1988 Feb;42(2):49–50. [PubMed] [Google Scholar]
  16. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1413–1418. doi: 10.1128/aac.33.9.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lassus A., Seppala A. Roxithromycin in nongonococcal urethritis. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):157–165. doi: 10.1093/jac/20.suppl_b.157. [DOI] [PubMed] [Google Scholar]
  18. Naess A., Solberg C. O. Effects of two macrolide antibiotics on human leukocyte membrane receptors and functions. APMIS. 1988 Jun;96(6):503–508. doi: 10.1111/j.1699-0463.1988.tb05336.x. [DOI] [PubMed] [Google Scholar]
  19. Nakayoshi T., Izumi M., Shinkai S., Fujita M. Comparative study on effects of 14- and 16-membered macrolides on gastrointestinal motility in unanaesthetized dogs. Drugs Exp Clin Res. 1988;14(5):319–325. [PubMed] [Google Scholar]
  20. Nelson S., Summer W. R., Terry P. B., Warr G. A., Jakab G. J. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. Am Rev Respir Dis. 1987 Nov;136(5):1207–1212. doi: 10.1164/ajrccm/136.5.1207. [DOI] [PubMed] [Google Scholar]
  21. Panteix G., Harf R., de Montclos H., Verdier M. F., Gaspar A., Leclercq M. Josamycin pulmonary penetration determined by broncho-alveolar lavage in man. J Antimicrob Chemother. 1988 Dec;22(6):917–921. doi: 10.1093/jac/22.6.917. [DOI] [PubMed] [Google Scholar]
  22. Prokesch R. C., Hand W. L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1982 Mar;21(3):373–380. doi: 10.1128/aac.21.3.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Raghoebar M., Lindeyer E., Van den Berg W. B., Van Ginneken C. A. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes. Biochem Pharmacol. 1988 Sep 1;37(17):3221–3227. doi: 10.1016/0006-2952(88)90631-4. [DOI] [PubMed] [Google Scholar]
  24. Rimoldi R., Fioretti M., Bandera M. Clinical experience with miocamycin in the treatment of respiratory tract infections. Drugs Exp Clin Res. 1985;11(4):263–268. [PubMed] [Google Scholar]
  25. Sakakibara H., Okekawa O., Fujiwara T., Aizawa M., Omura S. Acyl derivatives of 16-membered macrolides. II. Antibacterial activities and serum levels of 3"-O-acyl derivatives of leucomycin. J Antibiot (Tokyo) 1981 Aug;34(8):1011–1018. doi: 10.7164/antibiotics.34.1011. [DOI] [PubMed] [Google Scholar]
  26. Yoshida T., Watanabe T., Shomura T., Someya S., Okamoto R., Ishihara S., Miyauchi K., Kazuno Y. Bacteriological evaluation of midecamycin acetate and its metabolites. Jpn J Antibiot. 1982 Jun;35(6):1462–1474. [PubMed] [Google Scholar]
  27. van Rensburg C. E., Anderson R., Jooné G., van der Merwe M., van Rensburg A. J. Effects of erythromycin on cellular and humoral immune functions in vitro and in vivo. J Antimicrob Chemother. 1981 Dec;8(6):467–474. doi: 10.1093/jac/8.6.467. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES